{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:00:54Z","timestamp":1792000854264,"version":"4.4.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T00:00:00Z","timestamp":1684713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T00:00:00Z","timestamp":1684713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Imaging"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      CT prediction of resectability and prognosis following neoadjuvant treatment (NAT) in patients with pancreatic ductal adenocarcinoma (PDAC) remains challenging. This study aims to determine whether addition of\n                      <jats:sup>18<\/jats:sup>\n                      F-fluorodeoxyglucose (FDG) postiron emission tomography (PET)\/MRI and carbohydrate antigen (CA) 19\u20139 to contrast-enhanced CT (CECT) can improve accuracy of predicting resectability compared to CECT alone and predict prognosis in PDAC patients after NAT.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective study, 120 PDAC patients (65 women; mean age, 66.7\u00a0years [standard deviation, 8.4]) underwent CECT, PET\/MRI, and CA 19\u20139 examinations after NAT between January 2013 and June 2021. Three board-certified radiologists independently rated the overall resectability on a 5-point scale (score 5, definitely resectable) in three sessions (session 1, CECT; 2, CECT plus PET\/MRI\u2500no FDG avidity and no diffusion restriction at tumor-vessel contact indicated modification of CECT scores to\u2009\u2265\u20093; 3, CECT plus PET plus CA 19\u20139\u2500no FDG avidity at tumor-vessel contact and normalized CA 19\u20139 indicated modification of CECT scores to\u2009\u2265\u20093). Jackknife free-response receiver operating characteristic method and generalized estimating equations were used to compare pooled area under the curve (AUC), sensitivity, and specificity of three sessions. Predictors for recurrence-free survival (RFS) were assessed using Cox regression analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Each session showed different pooled AUC (session 1 vs. 2 vs. 3, 0.853 vs. 0.873 vs. 0.874,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.026), sensitivity (66.2% [137\/207] vs. 86.0% [178\/207] vs. 84.5% [175\/207],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and specificity (67.3% [103\/153] vs. 58.8% [90\/153] vs. 60.1% [92\/153],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.048). According to pairwise comparison, specificity of CECT plus PET\/MRI was lower than that of CECT alone (adjusted\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.042), while there was no significant difference in specificity between CECT alone and CECT plus PET plus CA 19\u20139 (adjusted\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.081). Twenty-eight of 69 patients (40.6%) with R0 resection experienced tumor recurrence (mean follow-up, 18.0\u00a0months). FDG avidity at tumor-vessel contact on post-NAT PET (HR\u2009=\u20094.37,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.033) and pathologically confirmed vascular invasion (HR\u2009=\u20095.36,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.004) predicted RFS.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Combination of CECT, PET and CA 19\u20139 increased area under the curve and sensitivity for determining resectability, compared to CECT alone, without compromising the specificity. Furthermore,\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG avidity at tumor-vessel contact on post-NAT PET predicted RFS.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40644-023-00565-8","type":"journal-article","created":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T07:02:17Z","timestamp":1684738937000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Post-neoadjuvant treatment pancreatic cancer resectability and outcome prediction using CT, 18F-FDG PET\/MRI and CA 19\u20139"],"prefix":"10.1186","volume":"23","author":[{"given":"Jeongin","family":"Yoo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0561-8777","authenticated-orcid":false,"given":"Jeong Min","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ijin","family":"Joo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Hee","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi Hye","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Young","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Hyub","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,22]]},"reference":[{"key":"565_CR1","unstructured":"Pancreatic Adenocarcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology [Internet]. 2022. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/pancreatic.pdf. Cited 22 Feb 2023"},{"issue":"6","key":"565_CR2","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S1470-2045(16)00172-8","volume":"17","author":"M Suker","year":"2016","unstructured":"Suker M, Beumer BR, Sadot E, Marthey L, Faris JE, Mellon EA, et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 2016;17(6):801\u201310.","journal-title":"Lancet Oncol"},{"issue":"3","key":"565_CR3","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/SLA.0000000000005249","volume":"275","author":"WL da Costa Jr","year":"2022","unstructured":"da Costa WL Jr, tran Cao HS, Gu X. Massarweh NN Bayesian Approach to Understand the Association Between Treatment Down-staging and Survival for Patients With Pancreatic Adenocarcinoma. Ann Surg. 2022;275(3):415\u201321.","journal-title":"Ann Surg"},{"issue":"9","key":"565_CR4","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jama.2021.13027","volume":"326","author":"W Park","year":"2021","unstructured":"Park W, Chawla A, O\u2019Reilly EM. Pancreatic Cancer: A Review. JAMA. 2021;326(9):851\u201362.","journal-title":"JAMA"},{"issue":"3","key":"565_CR5","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1007\/s00261-019-02289-5","volume":"45","author":"NM Kulkarni","year":"2020","unstructured":"Kulkarni NM, Soloff EV, Tolat PP, Sangster GP, Fleming JB, Brook OR, et al. White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology\u2019s disease-focused panel for pancreatic ductal adenocarcinoma: Part I, AJCC staging system, NCCN guidelines, and borderline resectable disease. Abdom Radiol (NY). 2020;45(3):716\u201328.","journal-title":"Abdom Radiol (NY)"},{"issue":"2","key":"565_CR6","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1148\/radiol.2018171670","volume":"287","author":"M Zins","year":"2018","unstructured":"Zins M, Matos C, Cassinotto C. Pancreatic Adenocarcinoma Staging in the Era of Preoperative Chemotherapy and Radiation Therapy. Radiology. 2018;287(2):374\u201390.","journal-title":"Radiology"},{"issue":"3","key":"565_CR7","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1007\/s10353-019-0598-5","volume":"51","author":"E-M Gassner","year":"2019","unstructured":"Gassner E-M, Poskaite P. Imaging response evaluation after novel neoadjuvant treatments of pancreatic cancer. Eur Surg. 2019;51(3):146\u201352.","journal-title":"Eur Surg"},{"issue":"2\u20133","key":"565_CR8","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1385\/IJGC:34:2-3:121","volume":"34","author":"AR Sasson","year":"2003","unstructured":"Sasson AR, Wetherington RW, Hoffman JP, Ross EA, Cooper H, Meropol NJ, et al. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: analysis of histopathology and outcome. Int J Gastrointest Cancer. 2003;34(2\u20133):121\u20138.","journal-title":"Int J Gastrointest Cancer"},{"issue":"6","key":"565_CR9","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/S1091-255X(01)80105-0","volume":"5","author":"RR White","year":"2001","unstructured":"White RR, Paulson EK, Freed KS, Keogan MT, Hurwitz HI, Lee C, et al. Staging of pancreatic cancer before and after neoadjuvant chemoradiation. J Gastrointest Surg. 2001;5(6):626\u201333.","journal-title":"J Gastrointest Surg"},{"issue":"5","key":"565_CR10","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1007\/s00330-020-07433-0","volume":"31","author":"S Park","year":"2021","unstructured":"Park S, Jang JK, Byun JH, Kim JH, Lee SS, Kim HJ, et al. CT in the prediction of margin-negative resection in pancreatic cancer following neoadjuvant treatment: a systematic review and meta-analysis. Eur Radiol. 2021;31(5):3383\u201393.","journal-title":"Eur Radiol"},{"issue":"4","key":"565_CR11","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ejrad.2012.12.002","volume":"82","author":"C Cassinotto","year":"2013","unstructured":"Cassinotto C, Cortade J, Belleann\u00e9e G, Lapuyade B, Terrebonne E, Vendrely V, et al. An evaluation of the accuracy of CT when determining resectability of pancreatic head adenocarcinoma after neoadjuvant treatment. Eur J Radiol. 2013;82(4):589\u201393.","journal-title":"Eur J Radiol"},{"issue":"3","key":"565_CR12","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1097\/SLA.0000000000005317","volume":"275","author":"F Bednar","year":"2022","unstructured":"Bednar F. Clinical Staging Uncertainty and Treatment Sequencing in Pancreatic Cancer. Ann Surg. 2022;275(3):422\u20133.","journal-title":"Ann Surg"},{"issue":"7","key":"565_CR13","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s12149-021-01629-0","volume":"35","author":"L Evangelista","year":"2021","unstructured":"Evangelista L, Zucchetta P, Moletta L, Serafini S, Cassarino G, Pegoraro N, et al. The role of FDG PET\/CT or PET\/MRI in assessing response to neoadjuvant therapy for patients with borderline or resectable pancreatic cancer: a systematic literature review. Ann Nucl Med. 2021;35(7):767\u201376.","journal-title":"Ann Nucl Med"},{"issue":"3","key":"565_CR14","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1148\/radiol.2016151975","volume":"280","author":"DH Lee","year":"2016","unstructured":"Lee DH, Lee JM, Hur BY, Joo I, Yi N-J, Suh K-S, et al. Colorectal cancer liver metastases: diagnostic performance and prognostic value of PET\/MR imaging. Radiology. 2016;280(3):782\u201392.","journal-title":"Radiology"},{"issue":"3","key":"565_CR15","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.mric.2018.03.003","volume":"26","author":"N Mallak","year":"2018","unstructured":"Mallak N, Hope TA, Guimaraes AR. PET\/MR Imaging of the Pancreas. Magn Reson Imaging Clin N Am. 2018;26(3):345\u201362.","journal-title":"Magn Reson Imaging Clin N Am"},{"issue":"1","key":"565_CR16","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1148\/radiol.2016152798","volume":"282","author":"I Joo","year":"2017","unstructured":"Joo I, Lee JM, Lee DH, Lee ES, Paeng JC, Lee SJ, et al. Preoperative Assessment of Pancreatic Cancer with FDG PET\/MR Imaging versus FDG PET\/CT Plus Contrast-enhanced Multidetector CT: A Prospective Preliminary Study. Radiology. 2017;282(1):149\u201359.","journal-title":"Radiology"},{"issue":"1","key":"565_CR17","doi-asserted-by":"publisher","first-page":"W10","DOI":"10.2214\/AJR.14.13818","volume":"206","author":"B Kang","year":"2016","unstructured":"Kang B, Lee JM, Song YS, Woo S, Hur BY, Jeon JH, et al. Added Value of Integrated Whole-Body PET\/MRI for Evaluation of Colorectal Cancer: Comparison With Contrast-Enhanced MDCT. AJR Am J Roentgenol. 2016;206(1):W10-20.","journal-title":"AJR Am J Roentgenol"},{"issue":"3","key":"565_CR18","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1080\/0284186X.2016.1256497","volume":"56","author":"EA Mellon","year":"2017","unstructured":"Mellon EA, Jin WH, Frakes JM, Centeno BA, Strom TJ, Springett GM, et al. Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy. Acta Oncol. 2017;56(3):391\u20137.","journal-title":"Acta Oncol"},{"issue":"1","key":"565_CR19","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00423-020-01857-4","volume":"405","author":"KI Okada","year":"2020","unstructured":"Okada KI, Kawai M, Hirono S, Kojima F, Tanioka K, Terada M, et al. Diffusion-weighted MRI predicts the histologic response for neoadjuvant therapy in patients with pancreatic cancer: a prospective study (DIFFERENT trial). Langenbecks Arch Surg. 2020;405(1):23\u201333.","journal-title":"Langenbecks Arch Surg"},{"issue":"2","key":"565_CR20","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.hpb.2019.06.012","volume":"22","author":"U Heger","year":"2020","unstructured":"Heger U, Sun H, Hinz U, Klaiber U, Tanaka M, Liu B, et al. Induction chemotherapy in pancreatic cancer: CA 19\u20139 may predict resectability and survival. HPB (Oxford). 2020;22(2):224\u201332.","journal-title":"HPB (Oxford)"},{"issue":"4","key":"565_CR21","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1097\/SLA.0000000000003049","volume":"271","author":"S Tsai","year":"2020","unstructured":"Tsai S, George B, Wittmann D, Ritch PS, Krepline AN, Aldakkak M, et al. Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. Ann Surg. 2020;271(4):740\u20137.","journal-title":"Ann Surg"},{"issue":"5","key":"565_CR22","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.2214\/AJR.17.18310","volume":"210","author":"I Joo","year":"2018","unstructured":"Joo I, Lee JM, Lee ES, Ahn SJ, Lee DH, Kim S-W, et al. Preoperative MDCT Assessment of Resectability in Borderline Resectable Pancreatic Cancer: Effect of Neoadjuvant Chemoradiation Therapy. Am J Roentgenol. 2018;210(5):1059\u201365.","journal-title":"Am J Roentgenol"},{"issue":"3","key":"565_CR23","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1148\/radiol.212236","volume":"303","author":"S-S Kim","year":"2022","unstructured":"Kim S-S, Lee S, Lee HS, Bang S, Han K, Park M-S. Retrospective Evaluation of Treatment Response in Patients with Nonmetastatic Pancreatic Cancer Using CT and CA 19\u20139. Radiology. 2022;303(3):548\u201356.","journal-title":"Radiology"},{"issue":"3","key":"565_CR24","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/ags3.12418","volume":"5","author":"H Akita","year":"2021","unstructured":"Akita H, Takahashi H, Eguchi H, Asukai K, Hasegawa S, Wada H, et al. Difference between carbohydrate antigen 19\u20139 and fluorine-18 fluorodeoxyglucose positron emission tomography in evaluating the treatment efficacy of neoadjuvant treatment in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma: Results of a dual-center study. Ann Gastroenterol Surg. 2021;5(3):381\u20139.","journal-title":"Ann Gastroenterol Surg"},{"issue":"4","key":"565_CR25","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1097\/SLA.0000000000002600","volume":"269","author":"T Michelakos","year":"2019","unstructured":"Michelakos T, Pergolini I, Castillo CF, Honselmann KC, Cai L, Deshpande V, et al. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX. Ann Surg. 2019;269(4):733\u201340.","journal-title":"Ann Surg"},{"issue":"2","key":"565_CR26","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s00330-020-07188-8","volume":"31","author":"JK Jang","year":"2021","unstructured":"Jang JK, Byun JH, Kang JH, Son JH, Kim JH, Lee SS, et al. CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy. Eur Radiol. 2021;31(2):813\u201323.","journal-title":"Eur Radiol"},{"issue":"1","key":"565_CR27","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3348\/kjr.2019.0862","volume":"22","author":"H Rhee","year":"2021","unstructured":"Rhee H, Park M-S. The Role of Imaging in Current Treatment Strategies for Pancreatic Adenocarcinoma. Korean J Radiol. 2021;22(1):23\u201340.","journal-title":"Korean J Radiol"},{"issue":"7","key":"565_CR28","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.hpb.2018.01.001","volume":"20","author":"E van Veldhuisen","year":"2018","unstructured":"van Veldhuisen E, Vogel JA, Klompmaker S, Busch OR, van Laarhoven HW, van Lienden KP, et al. Added value of CA19-9 response in predicting resectability of locally advanced pancreatic cancer following induction chemotherapy. HPB. 2018;20(7):605\u201311.","journal-title":"HPB"},{"issue":"3","key":"565_CR29","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.tranon.2015.04.003","volume":"8","author":"W-C Lin","year":"2015","unstructured":"Lin W-C, Chen J-H. Pitfalls and limitations of diffusion-weighted magnetic resonance imaging in the diagnosis of urinary bladder cancer. Translational oncology. 2015;8(3):217\u201330.","journal-title":"Translational oncology"},{"issue":"16","key":"565_CR30","doi-asserted-by":"publisher","first-page":"4866","DOI":"10.3390\/jcm11164866","volume":"11","author":"ML Sulciner","year":"2022","unstructured":"Sulciner ML, Ashley SW, Molina G. Advances and Remaining Challenges in the Treatment for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma. J Clin Med. 2022;11(16):4866.","journal-title":"J Clin Med"},{"issue":"2","key":"565_CR31","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.amjsurg.2017.05.007","volume":"214","author":"K Luberice","year":"2017","unstructured":"Luberice K, Downs D, Sadowitz B, Ross S, Rosemurgy A. Has survival improved following resection for pancreatic adenocarcinoma? Am J Surg. 2017;214(2):341\u20136.","journal-title":"Am J Surg"},{"issue":"3","key":"565_CR32","doi-asserted-by":"publisher","first-page":"730","DOI":"10.2214\/AJR.20.24567","volume":"217","author":"A Panda","year":"2021","unstructured":"Panda A, Garg I, Truty MJ, Kline TL, Johnson MP, Ehman EC, et al. Borderline Resectable and Locally Advanced Pancreatic Cancer: FDG PET\/MRI and CT Tumor Metrics for Assessment of Pathologic Response to Neoadjuvant Therapy and Prediction of Survival. AJR Am J Roentgenol. 2021;217(3):730\u201340.","journal-title":"AJR Am J Roentgenol"},{"issue":"3","key":"565_CR33","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1007\/s11307-020-01569-7","volume":"23","author":"FS Furtado","year":"2021","unstructured":"Furtado FS, Ferrone CR, Lee SI, Vangel M, Rosman DA, Weekes C, et al. Impact of PET\/MRI in the Treatment of Pancreatic Adenocarcinoma: a Retrospective Cohort Study. Mol Imaging Biol. 2021;23(3):456\u201366.","journal-title":"Mol Imaging Biol"},{"issue":"7","key":"565_CR34","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.3390\/jcm9072169","volume":"9","author":"C Sperti","year":"2020","unstructured":"Sperti C, Friziero A, Serafini S, Bissoli S, Ponzoni A, Grego A, et al. Prognostic Implications of 18-FDG Positron Emission Tomography\/Computed Tomography in Resectable Pancreatic Cancer. J Clin Med. 2020;9(7):2169.","journal-title":"J Clin Med"},{"issue":"6","key":"565_CR35","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s00259-014-2688-8","volume":"41","author":"HX Xu","year":"2014","unstructured":"Xu HX, Chen T, Wang WQ, Wu CT, Liu C, Long J, et al. Metabolic tumour burden assessed by 18F-FDG PET\/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection. Eur J Nucl Med Mol Imaging. 2014;41(6):1093\u2013102.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"565_CR36","doi-asserted-by":"publisher","first-page":"898","DOI":"10.2967\/jnumed.113.131847","volume":"55","author":"JW Lee","year":"2014","unstructured":"Lee JW, Kang CM, Choi HJ, Lee WJ, Song SY, Lee JH, et al. Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative 18F-FDG PET\/CT in Patients with Pancreatic Cancer. J Nucl Med. 2014;55(6):898\u2013904.","journal-title":"J Nucl Med"}],"container-title":["Cancer Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-023-00565-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40644-023-00565-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-023-00565-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T07:05:05Z","timestamp":1684739105000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerimagingjournal.biomedcentral.com\/articles\/10.1186\/s40644-023-00565-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,22]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["565"],"URL":"https:\/\/doi.org\/10.1186\/s40644-023-00565-8","relation":{},"ISSN":["1470-7330"],"issn-type":[{"value":"1470-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,22]]},"assertion":[{"value":"14 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by Seoul National University Hospital institutional review board, and the requirement for signed informed consent was waived due to the retrospective study design.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"49"}}